APA (7th ed.) Citation

Wu, Y., Tao, L., Liu, C., Wang, F., & Sun, S. (2025). Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China. International Journal of Clinical Pharmacy, 47(3), 737-746. https://doi.org/10.1007/s11096-025-01865-8

Chicago Style (17th ed.) Citation

Wu, Yao, Libo Tao, Chang Liu, Fangxu Wang, and Shuang Sun. "Cost-effectiveness Analysis of PD-L1 Testing Associated with Pembrolizumab for First-line Treatment of Advanced Non-small Cell Lung Cancer in China." International Journal of Clinical Pharmacy 47, no. 3 (2025): 737-746. https://doi.org/10.1007/s11096-025-01865-8.

MLA (9th ed.) Citation

Wu, Yao, et al. "Cost-effectiveness Analysis of PD-L1 Testing Associated with Pembrolizumab for First-line Treatment of Advanced Non-small Cell Lung Cancer in China." International Journal of Clinical Pharmacy, vol. 47, no. 3, 2025, pp. 737-746, https://doi.org/10.1007/s11096-025-01865-8.